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Short-term effect of preoperative intravenous iron therapy in
colorectal cancer patients with anemia: results of a cohort study
Michael Jordi Wilson,1,2 Jan Willem Dekker,3 Emma Bruns,4 Wernard Borstlap,4 Johannes Jeekel,5
Jaap Jan Zwaginga,6,7 and Martin Schipperus1,8
BACKGROUND: In the treatment of preoperative
anemia, which is associated with increased
postoperative morbidity, iron supplementation can
replace blood transfusion and erythropoiesis-stimulating
agents. The aim of this study was to assess the efficacy
of preoperative intravenous (IV) iron infusion in
optimizing hemoglobin (Hb) levels in anemic colorectal
cancer patients.
STUDY DESIGN AND METHODS: A retrospective
cohort study was performed on patients who underwent
surgery for colorectal cancer between 2010 and 2016 in
a single teaching hospital. The primary outcome
measure, the change in Hb level, was assessed by
comparing anemic patients receiving usual care (UC; i.e.
no iron therapy and no blood transfusion) with anemic
patients receiving IV iron therapy (no blood transfusion).
RESULTS: A total of 758 patients with colorectal cancer
were eligible, of whom 318 (41.9%) had anemia. The IV
and the UC groups included 52 and 153 patients with
mean Hb levels at diagnosis of 6.3 and 6.9 mmol/L,
respectively. In the IV group, preoperative Hb level was
significantly increased compared to the UC group (0.65
mmol/L vs. 0.10 mmol/L, p<0.001). High increase in Hb
level after iron infusion was associated with initial higher
transferrin and lower ferritin levels (high vs. poor
responders: median transferrin 2.9 g/L vs. 2.7 g/L,
median ferritin 12 mg/L vs. 27 mg/L).
CONCLUSION: Implementation of IV iron therapy in
anemic colorectal cancer patients leads to a distinct
increase of preoperative Hb level. IV iron therapy is most
effective in patients presenting with more severe anemia,
and with higher transferrin and lower ferritin levels,
markers for an absolute iron deficiency (ID), compared to
functional ID.
C
olorectal cancer is the third most commonly
diagnosed cancer in men and second in
women worldwide,1 and patients present with
anemia in up to one-third of the cases.2 Ane-
mia in this respect is emerging as an important health
problem. It is not only associated with fatigue3 and
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impaired physical performance and cognitive function,
but most importantly also with increased morbidity and
mortality.4-6
Iron deficiency (ID) is the most common cause of
preoperative anemia in colorectal cancer patients.7
Contributing mechanisms to the development of ID
anemia include chronic tumor-induced blood loss and
also impaired iron homeostasis associated with chronic
disease. While chronic blood loss will cause absolute
ID (AID), characterized by depleted iron stores,
impaired iron homeostasis will cause functional ID
(FID), characterized by reduced iron uptake and iron
mobilization from the reticuloendothelial system, both
leading to a reduction of biologically available iron for
erythropoiesis.8
Enhancement of a patient’s condition before surgery
has been gaining attention ever since the beneficial out-
comes of such protocols were shown.9,10 More specifically,
normalization of preoperative hemoglobin (Hb) level by
blood management strategy is an important element in
this spectrum of preoperative care.11-13
The high prevalence of ID anemia in colorectal can-
cer patients provides an opportunity to optimize preoper-
ative Hb level by preoperative iron supplementation with
the purpose of reducing the use of blood transfusions and
erythropoiesis-stimulating agents.14 Avoiding blood trans-
fusions and erythropoiesis-stimulating agents in onco-
logic patients seems important because of its association
with an increased risk of cancer recurrence and increased
mortality.15-17 Oral iron has been shown to correct ane-
mia, but is also known to be slow in terms of absorption
rate, to cause constipation, and to be ineffective in
patients with FID as oral iron is poorly absorbed in the
duodenum in these patients, due to increased production
of hepcidin.
Therefore, compared to oral iron, intravenous (IV)
iron therapy is likely to be more effective in treating
anemia, as shown in patients undergoing orthopedic18
or general abdominal surgery.19 Based on these advan-
tages, over the course of the past 5 years administration
of IV iron has also been introduced in our institution.
In this study, we retrospectively compare preoperative
IV iron with usual care (UC; i.e., no iron therapy) in
colorectal cancer patients with anemia, with regard to
increasing preoperative Hb level, and reducing postop-
erative complications and blood transfusions. In addi-
tion, predictive factors of good response to IV iron
therapy will be studied.
MATERIALS AND METHODS
Patient selection
All patients undergoing resection for colorectal cancer
between January 1, 2010, and July 1, 2016, at the
Department of Surgery, Reinier de Graaf Hospital, the
Netherlands, were identified. Patients who had surgery in
the emergency setting and those with missing data with
respect to baseline Hb levels and blood transfusions were
excluded.
Outcome measures
Primary outcome was the change in Hb level (i.e., Hb at
diagnosis – Hb preoperative), and secondary outcomes
included the percentage of patients with a blood transfu-
sion and complication less than 30 days postoperatively.
Defining patient groups
Consecutive patients diagnosed with anemia (men
Hb< 8.0 mmol/L, 12.9 g/dL; women Hb< 7.5 mmol/L,
12.0 g/dL) were eligible for inclusion. Initially, to provide a
clear overview, the total cohort with anemia was divided
in two main groups (IV vs. UC).
The UC group consisted of patients receiving UC,
defined by no IV iron therapy less than 6 weeks before sur-
gery. In general and after the disadvantages of oral iron
supplementation, none of the patients awaiting surgery in
our center did receive preoperative oral iron therapy.
According to the criteria of the Dutch Blood Transfusion
Guideline, during the entire study period, a blood transfu-
sion was given according to the 4-5-6 rule, depending on
the severity of the anemia and the condition of the
patient.20
The IV group consisted of patients receiving IV iron
therapy less than 6 weeks before surgery, defined by a
dose of 1000 to 2000 mg of iron(III)carboxymaltose (Ferin-
ject) or iron(III)isomaltoside (Monofer). In our institution,
a patient blood management (PBM) protocol was imple-
mented in July 2013. Before implementation of this proto-
col, treatment of preoperative anemia was heavily
depending on the interest in, and knowledge of, PBM of
each physician. As a result, there was heterogeneity in the
cohort of patients with anemia treated with IV iron ther-
apy before July 2013. As part of the implemented PBM
protocol, iron status was measured in all consecutive
patients diagnosed with colorectal cancer and treatment
with IV iron therapy was considered for patients with ane-
mia. However, each physician did have the possibility to
deviate from the PBM protocol, depending on their clini-
cal assessment. As a result, there was also heterogeneity in
the cohort of patients with anemia treated with IV iron
therapy after July 2013. Due to this heterogeneity, compar-
ing a before and after July 2013 cohort would not yield rel-
evant results.
In addition, two subgroups (IV vs. UC) were formed,
in which all factors possibly directly affecting Hb level
(i.e., preoperative blood transfusion and neoadjuvant che-
motherapy) were excluded. Patients receiving their first IV
iron infusion less than 7 days before surgery (IV group),
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and patients receiving IV iron infusion between 6 and 12
weeks before surgery (UC group) were additionally
excluded.
Statistical analyses
To assess the primary outcome, the difference between
Hb level at diagnosis and preoperative Hb level were cal-
culated and analyzed in the two subgroups. In addition,
predictive factors of good response to IV iron were identi-
fied. For comparison, chi-square and Mann-Whitney U
tests were performed. To assess the association between
IV iron therapy and postoperative blood transfusion and
complication, all patients with anemia (i.e., UC1 IV
group) were included in uni- and multivariable logistic
regression analyses. Among the variables included in the
logistic regression analyses is time frame surgery (2014-
2016 vs. 2010-2013), because in the course of time new
surgical techniques or procedures could potentially con-
tribute to a decrease in the postoperative blood transfu-
sion and complication rate. A significance level of 0.05
was considered to be significant.
Data collection
The use of preoperative IV iron therapy and pre-, peri-,
and postoperative blood transfusion was retrospectively
collected. In this respect, preoperative period was defined
as less than 6 weeks before surgery and postoperative
period as less than 30 days after surgery. In addition, Hb
values at diagnosis of colorectal cancer, before operation
(i.e., 1 day before surgery), and after operation (i.e., 1 day
after surgery) were manually obtained from medical
records. Clinical and pathologic data, including age, sex,
American Society of Anesthesiologists physical status clas-
sification (ASA classification), overall comorbidities (i.e.,
cardiologic, vascular, diabetes, pulmonic, neurologic,
thrombotic, urologic, musculoskeletal, infectious, malig-
nancy, endocrine) tumor type, pathologic tumor stage,
neoadjuvant treatment, and postoperative overall compli-
cations (i.e., pulmonic, cardiologic, thrombotic, infectious,
neurologic) were collected by the Dutch Surgical Colorec-
tal Audit, a disease-specific national audit.21 This audit
collects information on patient, tumor, treatment, and 30-
day and in-hospital outcome characteristics of all patients
undergoing a resection for primary colorectal carcinoma
in the Netherlands. The data set is based on evidence-
based guidelines and is cross-checked on a yearly basis
with data from the Netherlands Cancer Registry.
Ethical approval for this study was provided by the
Ethical Committee METC Zuidwest Holland (METC-nr
16-012, approved by secretary mw. drs. E. Roep, date of
approval 03/02/2016). Our institution, a teaching hospi-
tal, is making use of opt-out consent. Each included
patient had given consent by not declining to give
consent.
RESULTS
In total, 916 patients underwent surgery for colorectal
cancer. A total of 158 patients were excluded because of
missing data on blood transfusion or Hb level at diagnosis
or surgery in the emergency setting. A total of 318 patients
(41.9%) had anemia at diagnosis, of whom 94 patients
received IV iron treatment and 224 patients received UC.
After all factors possibly directly affecting Hb level were
excluded, 52 and 153 patients remained in the IV and UC
subgroup (Fig. 1).
IV versus UC, total cohort with anemia
An overview of the baseline characteristics is presented
in Table 1. Both groups had a mean age of more than
70 years (IV, 71.86 11.1; UC, 73.76 9.9; p5 0.15). In the
UC group, the majority was male compared to the IV
group (58.5% vs. 44.7%; p5 0.02) and there were more
patients with comorbidity (87.1% vs. 79.8%; p5 0.01)
and with a rectum tumor (20.5% vs. 5.3%; p5 0.001).
Regarding physical condition, surgical procedure, and
tumor stage, no significant differences were found. In
the IV group, Hb level at diagnosis was significantly
lower (6.12 mmol/L vs. 6.61 mmol/L; p< 0.001) and
more patients received a preoperative blood transfusion
(31.9% vs. 12.9%; p< 0.001). Of 30 IV patients addition-
ally receiving a preoperative blood transfusion, 13
patients (mean Hb level at diagnosis of 5.7 mmol/L)
received blood transfusion before iron infusion, while in
17 patients (mean Hb level at diagnosis of 5.7 mmol/L)
blood infusion was administered after iron transfusion.
Mean Hb level at diagnosis was considerably higher in
IV patients who did not receive preoperative blood
transfusion (6.3 mmol/L).
IV versus UC, subgroup
An overview of the baseline characteristics is presented in
Table 2. In total, 105 patients were included (IV, 52; UC,
153). In the IV group, 32 and 20 patients received a 1000
to 2000mg dose of iron(III)isomaltoside and iron(III)car-
boxymaltose, respectively. Both groups had a mean age of
more than 70 years (IV, 71.36 11.6; UC, 74.36 9.5;
p5 0.09). In the UC group, more males were included
compared to the IV group (60.8% vs. 44.2%; p5 0.04) and
there were more patients with a high ASA score (34% vs.
19.2%; p5 0.04). In the IV group, significantly more
patients were operated laparoscopically (82.7% vs. 64.7%;
p5 0.02). Regarding comorbidity, tumor localization and
tumor stage, no significant differences were found. In the
IV group, Hb level at diagnosis was significantly lower (6.3
mmol/L vs. 6.9 mmol/L; p< 0.001).
Patients with IV iron treatment showed a significantly
higher increase of Hb level compared to patients with UC
(IV 0.65 mmol/L vs. UC 0.10 mmol/L; p< 0.001). In
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TABLE 1. Patient baseline characteristics of all patients with anemia at diagnosis, IV group versus UC group*
Characteristic
IV group
(n5 94)
UC group
(n5 224) p value
Age (years) 71.8611.1 73.769.9 0.15
Sex (male) 42 (44.7) 131 (58.5) 0.02
ASA classification 0.06
I-II 71 (75.5) 145 (64.7)
III-IV 23 (24.5) 79 (35.3)
Comorbidity (overall) 75 (79.8) 195 (87.1) 0.01
Tumor localization 0.001
Colon 89 (94.7) 178 (79.5)
Rectum 5 (5.3) 46 (20.5)
TNM stage 0.68
I-II 59 (62.8) 135 (60.3)
III-IV 35 (37.2) 89 (39.7)
Surgery
Time frame 0.06
2010-2013 53 (56.4) 151 (67.4)
2014-2016 41 (43.6) 73 (32.6)
Laparoscopic (%) 72 (76.6) 153 (68.3) 0.14
Hb (mmol/L)
At diagnosis 6.1260.89 6.6160.87 <0.001
Number patients with preop. BT (%) | Hb at diagnosis (mmol/L) <0.001
Yes 30 (31.9) | 5.67 29 (12.9) | 5.56
Before iron infusion 13 | 5.68 NA
After iron infusion 17 | 5.67 NA
No 64 (68.1) | 6.32 195 (87.1) | 6.77
Number patients with postop. BT (%) | number of units transfused
Yes 10 (10.6) | 28 45 (20.1) | 91
No 84 (89.4) 179 (79.9)
Number patients with postop. complication (%)
Yes 24 (25.5) 77 (34.4)
No 70 (74.5) 147 (65.6)
*Data are reported as mean6SD or number (%)
BT5blood transfusion; postop.5 postoperative; preop.5preoperative; TNM5 tumor, node, and metastasis.
Fig. 1. Flow diagram.
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identifying characteristics associated with Hb level
response after iron infusion, patients receiving one dose
of iron infusion (1000 mg) were classified into high and
poor responders. A cutoff value of 0.6 mmol/L (i.e.,
median Hb level increase) was used (Table 3). In total, 33
patients were included (high responder, 17; poor
responder, 16). No significant differences were found for
age, sex, ASA score, comorbidity, tumor localization, and
tumor stage. Regarding iron status at diagnosis, high
responders showed more distinct signs of anemia and ID
compared to poor responders (high vs. poor responder;
median values, Hb 6.0 mmol/L vs 6.8 mmol/L, transferrin
saturation 5.3% vs. 11%). In addition, increased transferrin
(median, 2.9 g/L vs. 2.7 g/L) and decreased ferritin
(median, 12 mg/L vs. 27 mg/L) levels were found in the
high-responder group.
Association between IV iron therapy and
postoperative complications and blood
transfusions
All patients with anemia, as presented in Table 1, were
included in logistic regression analyses. In univariable
analysis, preoperative IV iron administration (odds ratio
[OR], 0.47; 95% confidence interval [CI], 0.23-0.99;
TABLE 2. Patient baseline characteristics and outcome, IV subgroup versus UC subgroup*
Characteristics IV (n552) UC (n5153) p value
Age (years) 71.3611.6 74.36 9.5 0.09
Sex (male) 23 (44.2) 93 (60.8) 0.04
ASA classification 0.045
I-II 42 (80.8) 101 (66.0)
III-IV 10 (19.2) 52 (34.0)
Comorbidity (overall) 11 (21.2) 21 (13.7) 0.20
Tumor localization 0.08
Colon 48 (92.3) 126 (82.4)
Rectum 4 (7.7) 27 (17.6)
TNM stage 0.36
I-II 34 (65.4) 89 (58.2)
III-IV 18 (34.6) 64 (41.8)
Surgery
Time frame 0.31
2010-2013 31 (59.6) 103 (67.3)
2014-2016 21 (40.4) 50 (32.7)
Laparoscopic (%) 43 (82.7) 99 (64.7) 0.02
Hb (mmol/L)
At diagnosis 6.360.8 6.960.7 <0.001
Outcome Hb (mmol/L) increase diagnosis-preop. 0.6560.74 0.1060.74 <0.001
*Data are reported as mean6SD or number (%)
preop.5preoperative; TNM5 tumor, node, and metastasis.
TABLE 3. Patient baseline characteristics, high responder (0.6 mmol/L Hb increase) versus poor responder
(<0.6 mmol/L Hb increase), receiving one-dose iron infusion (1000 mg)*
Characteristics
IV high responder
(n517)
IV poor responder
(n5 16) p value
Age (years) 69.36 13.1 73.66 9.0 0.28
Sex (male) 5 (29.4) 5 (31.2) 0.91
ASA classification 1.0
I-II 13 (76.5) 13 (81.2)
III-IV 4 (23.5) 3 (18.8)
Comorbidity (overall) 14 (82.4) 12 (75.0) 0.69
Tumor localization 0.60
Colon 16 (94.1) 14 (87.5)
Rectum 1 (5.9) 2 (12.5)
TNM stage 0.62
I-II 12 (70.6) 10 (62.5)
III-IV 5 (29.4) 6 (37.5)
Iron status at diagnosis
Hb (mmol/L) 6.0; 1.5 – 6.26 0.8 6.8; 1.1 – 6.660.7 0.10
TSAT (%) 5.3; 4.6 – 7.36 4.6 11; 15 – 16.36 14.3 0.02
Transferrin (g/L) 2.9; 0.4 – 3.16 0.5 2.7; 0.2 – 2.760.4 0.02
Ferritin (mg/L) 12; 27 – 36652 27; 67 – 1426 360 0.13
*Data are reported as mean6SD, number (%), or median; IQR – mean6SD.
TNM5 tumor, node, and metastasis; TSAT5 transferrin saturation.
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p5 0.04) was observed to prevent the administration of
postoperative blood transfusion. No significant result was
found in multivariable analysis (OR, 0.54; 95% CI, 0.24-
1.21; p5 0.14; Table 4). In both uni- and multivariable
analysis, no advantageous effect was found on postopera-
tive complications (OR, 0.66; 95% CI, 0.28-1.12; p5 0.12;
and OR, 0.91; 95% CI, 0.50-1.68; p5 0.77, respectively;
Table 5).
DISCUSSION
This study illustrates the efficacy of IV iron therapy in the
optimization of preoperative Hb level in colorectal cancer
patients with anemia, compared to UC. We found that IV
iron therapy is most effective in patients presenting with
more severe anemia and with higher transferrin and lower
ferritin levels, markers for an AID, compared to FID. In
this study, the distinct Hb increase after iron infusion did
not translate into an expected decrease in the percentage
of patients with a postoperative blood transfusion. This is
most likely due to the confounding effect of preoperative
blood transfusions, which could not be adequately cor-
rected for in this retrospective cohort. Our observed peri-
operative blood transfusion rates are fairly comparable
with the perioperative blood transfusion rates presented
in other large cohort studies,22,23 and our results, there-
fore, could legitimately be generalized.
Our results add to a growing body of evidence in the
literature demonstrating the efficacy of preoperative IV
iron therapy in colorectal cancer patients and contribute
TABLE 4. Regression analysis on relationship between preoperative IV iron and postoperative blood transfusion in
patients with anemia (n5 318)
Univariable Multivariable
Characteristics OR 95% CI p value OR 95% CI p value
Age (years) 1.02 0.99-1.05 0.23 1.02 0.99-1.06 0.26
Sex
Female vs. male 0.69 0.38-1.26 0.23 0.52 0.27 1.04 0.06
Comorbidity (overall) 1.27 0.54-2.99 0.59 1.04 0.39 2.74 0.94
ASA classification
III-IV vs. I-II 1.84 1.01-3.33 0.045 1.77 0.89-3.53 0.11
TNM stage
III-IV vs. I-II 0.72 0.39-1.33 0.30 0.66 0.34-1.28 0.22
Surgery
Laparoscopic vs. open 0.51 0.28-0.92 0.026 0.55 0.28-1.06 0.08
Tumor localization
Rectum vs. colon 1.03 0.47-2.26 0.94 1.10 0.98-1.24 0.12
Time frame surgery
2014-2016 vs. 2010-2013 0.69 0.37-1.30 0.25 0.65 0.32-1.32 0.24
Preoperative Hb (0.1 mmol/L increase) 0.48 0.33-0.69 <0.001 0.40 0.26-0.60 <0.001
Preoperative IV iron 0.47 0.23-0.99 0.046 0.54 0.24-1.21 0.14
TNM5 tumor, node, and metastasis.
TABLE 5. Regression analysis on relationship between preoperative IV iron and postoperative complications in
patients with anemia (n5 318)
Univariable Multivariable
Characteristics OR 95% CI p value OR 95% CI p value
Age (years) 1.01 0.99-1.03 0.51 1.02 0.99-1.04 0.30
Sex
Female vs. male 0.43 0.26-0.70 0.001 0.36 0.20-0.63 <0.001
Comorbidity (overall) 0.67 0.35-1.26 0.21 0.48 0.23-0.99 0.049
ASA classification
III-IV vs. I-II 1.54 0.94-2.53 0.09 1.62 0.90-2.90 0.11
TNM stage
III-IV vs. I-II 0.76 0.47-1.25 0.28 0.58 0.34-1.00 0.050
Surgery
Laparoscopic vs. open 0.33 0.20-0.55 <0.001 0.32 0.18-0.55 <0.001
Tumor localization
Rectum vs. colon 1.09 0.58-2.06 0.79 1.03 0.94-1.13 0.54
Time frame surgery
2014-2016 vs. 2010-2013 0.99 0.60-1.62 0.96 0.94 0.54-1.63 0.81
Preoperative Hb (0.1 mmol/L increase) 1.12 0.85-1.47 0.44 1.08 0.79-1.48 0.65
Preoperative IV iron 0.66 0.38-1.12 0.12 0.91 0.50-1.68 0.77
TNM5 tumor, node, and metastasis.
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to the ongoing debate whether preoperative IV iron ther-
apy is improving postoperative outcome. Our results are
consistent with the results of a prospective randomized
trial by Keeler and colleagues,24 comparing the effect of
preoperative oral versus IV iron in colorectal cancer
patients with anemia. No overall benefit was seen with IV
iron in reducing blood transfusions and postoperative
complications, despite the fact that in the study by Keeler
and colleagues oral iron administration represented UC.
However, in addition to the study by Keeler and col-
leagues, we also identified patients characteristics associ-
ated with Hb level response after iron infusion. Evidently,
higher transferrin and lower ferritin levels, markers for
AID, were associated with a higher Hb level response after
iron infusion. Increased ferritin level, a marker for FID,
could be the cause of poor Hb level response after iron
infusion. In this respect, increased uptake and retention of
the administered IV iron within cells of the reticuloendo-
thelial system may lead to a poor availability of adminis-
tered iron for erythropoiesis.8 Therefore, these results
stress the importance of distinguishing between the two
types of ID and emphasize the efficacy of IV iron namely
in patients with AID. It is noteworthy that in present inter-
national guidelines on the treatment of anemia in onco-
logic patients a distinction between type of ID is already
made: IV iron should be withheld in patients with an
active infection and/or if serum ferritin exceeds 1000 mg/
L.25,26 Despite this, in current clinical practice, no distinc-
tion is made between type of ID. Ongoing and future ran-
domized clinical trials must establish whether the
optimization of preoperative Hb level by preoperative IV
iron therapy is resulting in improved postoperative
outcome.11,13
A key strength of our study is the identification of
patient characteristics associated with Hb level response
after iron infusion in colorectal cancer patients. To our
knowledge, this is the first study identifying the potential
clinical relevance of identifying the type of ID in the treat-
ment of preoperative anemia not only with oral iron but
even with IV iron.
The main limitations of our study are threefold, lead-
ing to key recommendations for future research. First, this
study represents a retrospective cohort of consecutive
patients, involving several limitations. The significant dif-
ferences between the IV iron and UC group (e.g., baseline
Hb levels and time frame surgery) could, despite correc-
tion in the multivariable regressions analyses, potentially
indicate selection bias and have significant impact on the
outcome. Moreover, iron status was not consistently mon-
itored in each patient. In the past years, great efforts have
been made to optimize the results of colorectal cancer
surgery. In addition to surgical techniques and proce-
dures,9,10,27 blood transfusion strategy, as part of PBM, has
also changed in the course of time. In this regard, the opti-
mal transfusion threshold, dosing, and age of red blood
cell (RBC) units have been studied. At present, a restrictive
transfusion threshold is recommended for hospitalized
adult patients and seems to be safe in the oncologic set-
ting.28,29 Moreover, standard-issue RBC units rather than
fresh RBC units (storage length, <10 days) and, to initiate,
1 rather than 2 RBC units are advised.29 Although we cor-
rected our results for the year of treatment, the combined
efforts to optimize colorectal cancer care (e.g., centraliza-
tion, protocols, laparoscopy) might have contributed dif-
ferently to the results. This emphasizes the importance of
performing a randomized controlled trial comparing UC
(i.e., no therapy or oral iron) with IV iron supplementation
in colorectal cancer patients in which, importantly, IV iron
must be administered as early as possibly, preferably at
least 3 weeks before surgery for its optimal effect.11
Second, this study focused specifically on preopera-
tive treatment of anemia. However, investigation and
treatment of merely Hb levels appears to be a suboptimal
way to indicate overall performance and therefore, at pre-
sent, various multimodal programs are being intro-
duced.30,31 The use of such various modalities could be
valuable in preoperative prehabilitation, specifically in
elderly patients (>75 years), in which an increased 1-year
mortality of up to 25% is observed.32,33 In line with the
previous limitation, in this study, various multimodal pro-
grams may similarly introduce confounding of our results
that are not easily corrected for. A randomized trial could
correct for both continuing pre- as well as postoperative
care optimization.
The third limitation was that only short-term effects
of IV iron therapy were studied. In this respect, iron is an
important growth factor for rapidly proliferating cells,
including bacteria and tumor cells.8,34 Several animal
experiment studies have shown exposure to iron to be a
risk factor for developing colorectal cancer and tumor
growth.35,36 In this regard, intraluminal colorectal tumors
might be more affected by oral iron administration, while
IV iron with a higher risk of non–transferrin-bound serum
iron and reactive oxygen species presence might also
influence systemic tumor growth. Randomized trials on
the short-term benefits versus the potential long-term
hazards of iron therapy in colorectal cancer patients
should therefore acknowledge the type of anemia and the
associated choice of iron therapy.
In conclusion, we were able to show that implemen-
tation of IV iron therapy leads to optimization of preoper-
ative Hb level. Furthermore, we showed the importance of
assessing the type of ID. Iron infusion is most effective in
patients with more severe anemia and with higher trans-
ferrin and lower ferritin levels, markers for AID, compared
to FID. After the optimization of preoperative Hb level,
strikingly, no significant decrease in the percentage of
patients with a postoperative blood transfusion and post-
operative complication were observed. However, from this
cohort study, due to its retrospective nature, we cannot
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entirely conclude that IV iron and the associated Hb
increase does decrease the postoperative blood transfu-
sion and complication rate. Future randomized trials are
thus required to not only establish the short-term bene-
fits, but also the potential long-term hazards of preopera-
tive IV iron therapy in colorectal cancer patients.
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